Skip to content
sellWeak cluster of 210b5-1 plan

Kathryn Guarini sold $320k of REGN

director at REGENERON PHARMACEUTICALS, INC.. 400 shares at an average of $800.00, traded Aug 10, 2026, filed Aug 12, 2026.

Warning score
12
Value
$320k
400 shares
Holdings after
603
-40% from before
From 52-week low
+49%
low $542.33, close $807.11
From 52-week high
-0%
high $809.14, as of Aug 10, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $320k at market
    +14
  • Share of holdings sold
    Sold 40% of holdings
    +10
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

REGNOct 13, 2026 · close 753.12
Since filing Aug 12, 2026: -5.5%SPY +1.0% · excess -6.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001992352-26-000005, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 10, 2026MOption exercise
Common Stock10b5-1
+400$719.37$288k1,003Aug 12, 2026
Aug 10, 2026SOpen-market sale
Common Stock10b5-1
-400$800.00$320k603Aug 12, 2026
Aug 10, 2026MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-400$0.00$01,558Aug 12, 2026

Related signals

Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
13Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Kathryn Guarini
director
$340k
400 shares
-40%
33Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Marion McCourt
EVP Commercial
$2.0M
2,346 shares
-16%
18Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Huda Y Zoghbi
director
$640k
800 shares
-32%
6Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$130k
200 shares
-1%
3Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$71k
100 shares
-1%
4Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$78k
100 shares
-1%
12Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$79k
100 shares
-1%
30Weak
REGNsell 310b5-1
REGENERON PHARMACEUTICALS, INC.
Huda Y Zoghbi
director
$1.3M
1,638 shares
-49%
30Weak
REGNsell 310b5-1
REGENERON PHARMACEUTICALS, INC.
Jason Pitofsky
SVP Controller
$1.6M
2,036 shares
-32%
19Weak
REGNsell 310b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$78k
100 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kathryn Guarini sold $320k of REGN | InsiderTell